Overview

A Study to Evaluate the Safety, Tolerability and the Effects of Ixodes Ricinus-Contact Phase Inhibitor (Ir-CPI) in Adult Patients With Spontaneous Intracerebral Haemorrhage

Status:
Recruiting
Trial end date:
2027-07-01
Target enrollment:
Participant gender:
Summary
The purpose of the study is to provide a first assessment of safety, tolerability and efficacy of Ir-CPI, administered on top of standard-of-care, on secondary brain injury in patients with spontaneous intracerebral haemorrhage.
Phase:
Phase 2
Details
Lead Sponsor:
Bioxodes S.A.